Advaita Bioinformatics is a spin-off from Wayne State University. As Dr Draghici, Founder & CEO explained, thousands of drugs fail during Phase III clinical trials. Why is this happening? "The problem is that no two patients are the same. Drugs fail because one cannot currently distinguish between patients who will respond and patients who will not respond or have adverse effects." A technology that could distinguish between people who respond favorably those who will not would allow drugs to be FDA approved much sooner, and save the pharmaceutical industry over $900 million dollars. What is Advaita's solution? Their technology is able to: improve the success of clinical trials by discerning between respondents and non-respondents; design optimal treatments by distinguishing between more and less aggressive types of diseases; re-purpose drugs; and predict side effects. Their product is available as a Software as a Service (SaaS) solution and their primary customers are small biotech firms, pharmaceutical companies and contract research organizations (CROs). Visit them at Advaita Bio.